口服地屈孕酮与微粉化阴道黄体酮用于黄体期支持:一项双盲交叉研究探讨药代动力学及对子宫内膜的影响
该研究在30名计划接受两个卵巢刺激周期的卵母细胞捐献者中,以随机、交叉、双盲、双模拟方式比较口服地屈孕酮(O-DYD)与微粉化阴道黄体酮(MVP)用于黄体期支持(LPS)时的血浆浓度、子宫内膜组织学、转录组及免疫细胞组成。21名女性完成全部方案;O-DYD后血浆地屈孕酮(D)和20α二氢地屈孕酮(DHD)浓度出现峰值,但两种LPS的子宫内膜组织学和转录组特征相似。
要点
- O-DYD后D和DHD血浆浓度出现峰值,但子宫内膜组织学与转录组特征与MVP相似。
- RNA测序未发现两组间显著差异表达基因。
- MVP后CD3 T细胞、γδ T细胞和B细胞频率较O-DYD降低,NK细胞频率显著增加。
核心结论
- O-DYD后即使达稳态,血浆D和DHD浓度较P出现峰值,但子宫内膜组织学和转录组分析显示相似的子宫内膜特征。
- 分子子宫内膜数据总体可比,支持先前报道的O-DYD较MVP非劣效的生殖结局。
研究设计与样本
- 计划30名卵母细胞捐献者接受两个卵巢刺激周期,每个周期采用双触发(1.000 IU hCG + 0.2 mg曲普瑞林),随后1周LPS:O-DYD或MVP,随机、交叉、双盲、双模拟设计。
- LPS第1天和第8天首次给药后采集系列血样分析血浆D、DHD和P浓度;第8天采集子宫内膜活检进行组织学、转录组和免疫细胞分析。
- 最终21名女性完成全部研究方案。
主要发现
- O-DYD首次给药后D和DHD平均观察最大血浆浓度(Cmax)分别为2.9和77 ng/ml,达峰时间(Tmax)分别为1.5和1.6 h。
- LPS第8天首次给药后D和DHD的Cmax分别为3.6和88 ng/ml,Tmax均为1.5 h。
- MVP首次给药后P的Cmax为16 ng/ml,Tmax为4.2 h;LPS第8天首次给药后P的Cmax为21 ng/ml,Tmax为7.3 h。
- 全部42份活检均显示分泌期子宫内膜;平均周期天数O-DYD组为23.9(±1.2)天,MVP组为24.0(±1.3)天。
- RNA测序未显示两组样本间显著差异表达基因;O-DYD后样本间平均欧氏距离显著低于MVP后(分别为12.1 vs 18.8,Mann-Whitney P = 6.98e-14)。
关键数值与推荐
- O-DYD首次给药后D的Cmax为2.9 ng/ml,DHD的Cmax为77 ng/ml;LPS第8天首次给药后D的Cmax为3.6 ng/ml,DHD的Cmax为88 ng/ml。
- MVP首次给药后P的Cmax为16 ng/ml;LPS第8天首次给药后P的Cmax为21 ng/ml。
- O-DYD后样本间平均欧氏距离为12.1,MVP后为18.8(Mann-Whitney P = 6.98e-14)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要局限为样本量小,鉴于项目的基础研究性质。
- 血浆浓度仅为最佳估计,因非正式药代动力学研究。
- 全组织批量RNA测序未校正活检间组织组成差异所致的偏倚。
- 需进一步研究探讨O-DYD后较小的样本间距离及子宫内膜免疫细胞的细微变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: How do plasma progesterone (P) and dydrogesterone (D) concentrations together with endometrial histology, transcriptomic signatures, and immune cell composition differ when oral dydrogesterone (O-DYD) or micronized vaginal progesterone (MVP) is used for luteal phase support (LPS)? SUMMARY ANSWER: Although after O-DYD intake, even at steady-state, plasma D and 20αdihydrodydrogesterone (DHD) concentrations spiked in comparison to P concentrations, a similar endometrial signature was observed by histological and transcriptomic analysis of the endometrium. WHAT IS KNOWN ALREADY: O-DYD for LPS has been proven to be noninferior compared to MVP in two phase III randomized controlled trials. Additionally, a combined individual participant data and aggregate data meta-analysis indicated that a higher pregnancy rate and live birth rate may be obtained in women receiving O-DYD versus MVP for LPS in fresh IVF/ICSI cycles. Little data are available on the pharmacokinetic (PK) profiles of O-DYD versus MVP and their potential molecular differences at the level of the reproductive organs, particularly at the endometrial level. STUDY DESIGN, SIZE, DURATION: Thirty oocyte donors were planned to undergo two ovarian stimulation (OS) cycles with dual triggering (1.000 IU hCG + 0.2 mg triptorelin), each followed by 1 week of LPS: O-DYD or MVP, in a randomized, cross-over, double-blind, double-dummy fashion. On both the first and eighth days of LPS, serial blood samples upon first dosing were harvested for plasma D, DHD, and P concentration analyses. On Day 8 of LPS, an endometrial biopsy was collected for histologic examination, transcriptomics, and immune cell analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: All oocyte donors were <35 years old, had regular menstrual cycles, no intrauterine contraceptive device, anti-Müllerian hormone within normal range and a BMI ≤29 kg/m2. OS was performed on a GnRH antagonist protocol followed by dual triggering (1.000 IU hCG + 0.2 mg triptorelin) as soon as ≥3 follicles of 20 mm were present. Following oocyte retrieval, subjects initiated LPS consisting of MVP 200 mg or O-DYD 10 mg, both three times daily. D, DHD, and P plasma levels were measured using liquid chromatography-tandem mass spectrometry. Histological assessment was carried out using the Noyes criteria. Endometrial RNA-sequencing was performed for individual biopsies and differential gene expression was analyzed. Endometrial single-cell suspensions were created followed by flow cytometry for immune cell typing. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 21 women completed the entire study protocol. Subjects and stimulation characteristics were found to be similar between groups. Following the first dose of O-DYD, the average observed maximal plasma concentrations (Cmax) for D and DHD were 2.9 and 77 ng/ml, respectively. The Cmax for D and DHD was reached after 1.5 and 1.6 h (=Tmax), respectively. On the eighth day of LPS, the first administration of that day gave rise to a Cmax of 3.6 and 88 ng/ml for D and DHD, respectively. For both, the observed Tmax was 1.5 h. Following the first dose of MVP, the Cmax for P was 16 ng/ml with a Tmax of 4.2 h. On the eighth day of LPS, the first administration of that day showed a Cmax for P of 21 ng/ml with a Tmax of 7.3 h. All 42 biopsies showed endometrium in the secretory phase. The mean cycle day was 23.9 (±1.2) in the O-DYD group versus 24.0 (±1.3) in the MVP group. RNA-sequencing did not reveal significantly differentially expressed genes between samples of both study groups. The average Euclidean distance between samples following O-DYD was significantly lower than following MVP (respectively 12.1 versus 18.8, Mann-Whitney P = 6.98e-14). Immune cell profiling showed a decrease of CD3 T-cell, γδ T-cell, and B-cell frequencies after MVP treatment compared to O-DYD, while the frequency of natural killer (NK) cells was significantly increased. LIMITATIONS, REASONS FOR CAUTION: The main reason for caution is the small sample size, given the basic research nature of the project. The plasma concentrations are best estimates as this was not a formal PK study. Whole tissue bulk RNA-sequencing has been performed not correcting for bias caused by different tissue compositions across biopsies. WIDER IMPLICATIONS OF THE FINDINGS: This is the first study comparing O-DYD/MVP, head-to-head, in a randomized design on a molecular level in IVF/ICSI. Plasma serum concentrations suggest that administration frequency is important, in addition to dose, specifically for O-DYD showing a rapid clearance. The molecular endometrial data are overall comparable and thus support the previously reported noninferior reproductive outcomes for O-DYD as compared to MVP. Further research is needed to explore the smaller intersample distance following O-DYD and the subtle changes detected in endometrial immune cells. STUDY FUNDING/COMPETING INTEREST(S): Not related to this work, C.Bl. has received honoraria for lectures, presentations, manuscript writing, educational events, or scientific advice from Abbott, Ferring, Organon, Cooper Surgical, Gedeon-Richter, IBSA, and Merck. H.T. has received honoraria for lectures, presentations, manuscript writing, educational events, or scientific advice from Abbott, Ferring, Cooper Surgical, Gedeon-Richter, Cook, and Goodlife. S.M. has received honoraria for lectures, presentations, educational events, or scientific advice from Abbott, Cooper Surgical, Gedeon-Richter, IBSA, and Merck and Oxolife. G.G. has received honoraria for lectures, presentations, educational events, or scientific advice from Merck, MSD, Organon, Ferring, Theramex, Gedeon-Richter, Abbott, Biosilu, ReprodWissen, Obseva, PregLem, Guerbet, Cooper, Igyxos, and OxoLife. S.V.-S. is listed as inventor on two patents (WO2019115755A1 and WO2022073973A1), which are not related to this work. TRIAL REGISTRATION NUMBER: EUDRACT 2018-000105-23.
引用
- Loreti S, Thiele K, De Brucker M, et al. Oral dydrogesterone versus micronized vaginal progesterone for luteal phase support: a double-blind crossover study investigating pharmacokinetics and impact on the endometrium. Hum Reprod. 2024. PMID: 38110714. doi:10.1093/humrep/dead256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。